6681-15-8
基本信息
鹽酸藥根堿
藥根堿鹽酸鹽
鹽酸藥根堿(標準品)
鹽酸藥根堿(藥根堿鹽酸鹽)
鹽酸藥根堿, 來源于十大功勞
Neprotine chloride
Yatrorhizine chloride
JATRORRHIZINE HCL(RG)
Jatrochizine chloride
Jatorrhizine, chloride
(960383-96-4) jatrorrhizine hydrochloride
Jatrorrhizine,Neprotine chloride,Yatrorhizine chloride
Jatrorrhizine hydrochloride, 98%, from Mahonia fortunei (Lindl.) Fedde
物理化學性質
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/11/08 | S9069 | 鹽酸藥根堿 Jatrorrhizine chloride | 6681-15-8 | 1mg | 876.72元 |
2023/01/06 | XW66811581 | 鹽酸藥根堿 jatrorrhizine hydrochloride;jatrorrhizine chloride;neprotine chloride;2,9,10-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol chloride | 6681-15-8 | 20MG | 388元 |
常見問題列表
Target | Value |
AChE
() | 872 nM |
Jatrorrhizine has antiplasmodial and antiamoebic activity, it against Plasmodium falciparum and E. histolytica with IC 50 values of 3.15 and 82.7 μM, respectively.The hOCT2 (organic cation transporter 2), hOCT3, and PMAT (plasma membrane monoamine transporter) are capable of transporting monoamine neurotransmitters in the brain. Jatrorrhizine has the inhibitory potency of jatrorrhizine on 5-HT and NE uptake in hOCT2-, hOCT3-, and PMAT-transfected cells. Jatrorrhizine strongly inhibits PMAT-mediated MPP + uptake with an IC 50 value of 1.05 μM and reduces 5-HT and NE uptake mediated by hOCT2, hOCT3, and hPMAT with IC 50 values of 0.1-1 μM (for OCT2 and OCT3) and 1-10 μM (for PMAT).Clearance of neurotransmitters released into the synaptic cleft is defined by two distinct processes. Uptake-1, the common target of current applied antidepressants, is comprised of the serotonin transporter (SERT), the “SERT”, had a high affinity but low capacity to take up [3H]5-HT. Uptake-2 transporters are an important supplementary regulation system in monoamine clearancethought to be the “NET”, has low affinity but high capacity to take up [ 3 H]5-HT into brain slices. Jatrorrhizine significantly inhibited 5-HT and NE uptake in synaptosomes at 25 μM and 50 μM.
Jatrorrhizine chloride (intraperitoneal?injection; 5, 10, 20 mg/kg) can significantly reduce the duration of immobility when compared with vehicle control group in tail suspension test (TST).
Animal Model: | Male ICR albino mice |
Dosage: | 5, 10, 20 mg/kg |
Administration: | Intraperitoneal?injection; 5, 10, 20 mg/kg |
Result: | Reduced immobility period in tail suspension test. |